World's Best Scientists 2026 revealed!
Christoph Huber

Christoph Huber

D-Index & Metrics

Immunology

D-Index
87
Citations
32406
World Ranking
1204
National Ranking
77

Christoph Huber publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Christoph Huber sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 432 publications — 84th percentile

84% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Christoph Huber D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Christoph Huber sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 87 D-Index — 76th percentile

76% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Christoph Huber is affiliated with BioNTech in Germany and has contributed extensively to the field of medicine, with a strong focus on cardiology and cardiovascular medicine. Their research work spans multiple subfields including pulmonary and respiratory medicine, surgery, epidemiology, and immunology.

The scientist has published over a hundred papers in medicine, with notable emphasis on cardiovascular topics. The main topics covered in their research include:

  • Cardiac Valve Diseases and Treatments
  • Infective Endocarditis Diagnosis and Management
  • Aortic Aneurysm Repair Treatments
  • Aortic Disease and Treatment Approaches
  • Mechanical Circulatory Support Devices
  • Atrial Fibrillation Management and Outcomes
  • Cardiac Structural Anomalies and Repair

Huber has collaborated frequently with several researchers, among them:

  • Mustafa Çıkırıkçıoğlu
  • Nicolas Mürith
  • Stefan Stortecky
  • Olivier Müller
  • Stefan Toggweiler

The scientist's work has been published in various peer-reviewed venues, with several papers appearing in cardiovascular-focused journals. The frequent publication venues include:

  • JACC: Cardiovascular Interventions
  • Journal of Clinical Medicine
  • Regular and Young Investigator Award Abstracts
  • Revue Médicale Suisse
  • The International Journal of Artificial Organs

Some recent notable papers authored or co-authored by Christoph Huber are:

  • "FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma," 2021, Annals of Oncology
  • "Infective Endocarditis After Transcatheter Aortic Valve Replacement," 2020, Journal of the American College of Cardiology
  • "Age-Related Outcomes After Transcatheter Aortic Valve Replacement," 2021, JACC: Cardiovascular Interventions
  • "Clinical Outcomes in High-Gradient, Classical Low-Flow, Low-Gradient, and Paradoxical Low-Flow, Low-Gradient Aortic Stenosis After Transcatheter Aortic Valve Implantation: A Report From the SwissTAVI Registry," 2023, Journal of the American Heart Association
  • "Long-Term Risk of Stroke After Transcatheter Aortic Valve Replacement," 2023, JACC: Cardiovascular Interventions

Best Publications

  • Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer

    Ugur Sahin;Evelyna Derhovanessian;Matthias Miller;Björn-Philipp Kloke

  • Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy

    Lena M. Kranz;Mustafa Diken;Heinrich Haas;Sebastian Kreiter

  • Mutant MHC class II epitopes drive therapeutic immune responses to cancer

    Sebastian Kreiter;Mathias Vormehr;Niels van de Roemer;Mustafa Diken

  • Serum levels of cytokines in chronic liver diseases.

    Herbert Tilg;Herbert Tilg;Axel Wilmer;Axel Wilmer;Wolfgang Vogel;Wolfgang Vogel;Manfred Herold;Manfred Herold

  • Cancer classification using the Immunoscore: a worldwide task force

    Jérôme Galon;Franck Pagès;Francesco M Marincola;Francesco M Marincola;Helen K Angell;Helen K Angell

  • Exploiting the mutanome for tumor vaccination

    John C. Castle;Sebastian Kreiter;Jan Diekmann;Martin Löwer

  • An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma.

    Ugur Sahin;Petra Oehm;Evelyna Derhovanessian;Robert A. Jabulowsky

  • Actively personalized vaccination trial for newly diagnosed glioblastoma

    Norbert Hilf;Sabrina Kuttruff-Coqui;Katrin Frenzel;Valesca Bukur

  • Therapeutic vaccines for cancer: an overview of clinical trials

    Ignacio Melero;Gustav Gaudernack;Winald Gerritsen;Christoph Huber

  • Modification of antigen encoding RNA increases stability, translational efficacy and T-cell stimulatory capacity of dendritic cells

    Silke Holtkamp;Sebastian Kreiter;Abderraouf Selmi;Petra Simon

  • The response of autologous T cells to a human melanoma is dominated by mutated neoantigens

    Volker Lennerz;Martina Fatho;Chiara Gentilini;Roy A. Frye

  • Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody Development

    Ugur Sahin;Michael Koslowski;Karl Dhaene;Dirk Usener

  • Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer.

    Thomas Stanislawski;Ralf-Holger Voss;Carina Lotz;Elena Sadovnikova

  • Intranodal Vaccination with Naked Antigen-Encoding RNA Elicits Potent Prophylactic and Therapeutic Antitumoral Immunity

    Sebastian Kreiter;Abderraouf Selmi;Mustafa Diken;Michael Koslowski

  • Adenovirus-Mediated Wild-Type p53 Gene Transfer in Patients Receiving Chemotherapy for Advanced Non–Small-Cell Lung Cancer: Results of a Multicenter Phase II Study

    M. Schuler;R. Herrmann;J. L.P. De Greve;A. K. Stewart

  • Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells.

    Barbara Seliger;Ursula Wollscheid;Frank Momburg;Thomas Blankenstein

  • Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway.

    Barbara Seliger;Ulrike Ritz;Rupert Abele;Michaela Bock

  • Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo

    A N Kuhn;M Diken;S Kreiter;A Selmi

  • Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies?

    Elena Neumann;Arne Engelsberg;Jochen Decker;Stephan Störkel

  • A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer.

    Martin Schuler;Christoph Rochlitz;Jo Ann Horowitz;Jens Schlegel

  • Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma.

    W Aulitzky;G Gastl;W E Aulitzky;M Herold

Frequent Co-Authors

Ugur Sahin
Ugur Sahin Johannes Gutenberg University of Mainz
Juergen Huber
Juergen Huber University of Innsbruck
Özlem Türeci
Özlem Türeci BioNTech (Germany)
Michael Kirchler
Michael Kirchler University of Innsbruck
Herbert Tilg
Herbert Tilg Innsbruck Medical University
Christian Peschel
Christian Peschel Technical University of Munich
Manfred Herold
Manfred Herold Innsbruck Medical University
Barbara Seliger
Barbara Seliger Martin Luther University Halle-Wittenberg
Hans-Georg Rammensee
Hans-Georg Rammensee University of Tübingen
Andreas Kuhn
Andreas Kuhn University of Hohenheim

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in immunology, pursuing complementary healthcare degrees online can open diverse career opportunities. Many professionals start with accessible programs like accredited LPN programs easy to get into, providing foundational nursing skills essential for patient care and laboratory work.

If you’re transitioning from a non-nursing background, exploring online BSN programs for non nurses offers a flexible pathway to gain a Bachelor of Science in Nursing. These programs often include specialized training that complements immunology knowledge.

For faster entry into nursing careers, accelerated BSN programs for non nurses provide an intensive, shorter route suitable for those eager to blend clinical practice with immunology research roles.

Advancing even further, individuals can opt for easiest online nurse practitioner programs to specialize and lead in patient care, policy, or immunological consultancy. These pathways highlight the synergy between immunology and nursing professions, enhancing career prospects in both fields.

Best Scientists Citing Christoph Huber

Trending Scientists

Recently Published Articles